Key result
Aggressive hypotensive-drug therapy resulted in 55% (11/20) 1-year survival in patients with malignant hypertension and renal insufficiency, without necessarily deteriorating renal function.
Why the study?
Does aggressive hypotensive-drug therapy improve survival in patients with malignant hypertension complicated by renal insufficiency?
Observational (n=20)
Does aggressive hypotensive-drug therapy improve survival in patients with malignant hypertension complicated by renal insufficiency?
Aggressive blood pressure reduction in malignant hypertension with renal insufficiency may prolong survival without necessarily causing deterioration of renal function.
Answers are grounded in this paper and cite their sources.
May support aggressive BP control in malignant hypertension with renal insufficiency; hypothesis-generating case series requiring randomized confirmation.
Aggressive hypotensive-drug therapy combining a thiazide diuretic, hydralazine and guanethedine was used in 20 patients with malignant hypertension complicated by renal insufficiency. Eleven of the patients lived for one year, four for five years, and two for 7 1/2 years. One is still alive beyond eight years. The glomerular filtration rate remained stable at low levels for long periods in some of the patients. Eleven died of uremia. In patients surviving for only weeks or months, the arterioles and small arteries were most affected, whereas in those surviving for at least one year, the large arteries revealed the more striking pathological changes. We conclude that aggressive reduction of blood pressure does not necessarily result in deterioration of renal function and may prolong survival. (N Engl J Med 291:10–14, 1974)
No takes yet. Share an insight, caveat, or question.
Woods et al. (1974) conducted an observational in Malignant hypertension complicated by renal insufficiency (n=20). Aggressive hypotensive-drug therapy (thiazide diuretic, hydralazine, and guanethedine) was evaluated on 1-year survival. Aggressive hypotensive-drug therapy resulted in 55% (11/20) 1-year survival in patients with malignant hypertension and renal insufficiency, without necessarily deteriorating renal function.
Synapse has enriched 10 related papers. Consider them for comparative context: